Loading Results

CAR T

Showing   of 5 results

BAFF CAR T

Phase 1 BAFF CAR T Clinical Trial for Patients with Relapsed and Refractory Multiple Myeloma Underway at UH Seidman Cancer Center

Study is being done through an agreement between UH and Luminary Therapeutics.

CID group logos

Cleveland Innovation District Partners Exceeding Many Targets Set by State and JobsOhio

25 examples of progress showcase the impact of successful collaboration.

Team Led by University Hospitals Seidman Cancer Center Researcher Develops and Validates Three-in-One CAR T Therapy

Research detailed in the journal Nature Communications shows therapeutic potential of BAFF CART for treating multiple B cell cancers, using mouse models with high effectiveness and minimum  side effects

New Clinical Trials from University Hospitals Seidman Cancer Center to Begin with Human Protein

Follows successful on-site approach to producing and using anti-CD19 CAR T-Cells against B-cell malignancies; significant findings published in the journal Nature Communications this month.

UH Seidman CAR-T lab

University Hospitals First in Ohio to Treat Patients with Two FDA-Approved CAR T Cancer Therapies

Latest immunotherapies target multiple myeloma and diffuse large B-cell lymphoma.

Results are loading...